It is also possible that the amyloid hypothesis is somewhat on the right track, but just need to target the right part of the pathway. For example no one has designed any clinical trial yet according to this article recently published in the journal Nature (a Gal3 inhibitor drug, belapectin, currently exists):
Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer’s disease
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology